Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS9 | O00182 | 1/20 | 0.40 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.40 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.40 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 3/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.36 |
| ▸ | HTR3B | O95264 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.36 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14616525 | 1.00 | LGALS9 (0.40) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA | |
| SCHEMBL15394247 | 1.00 | LGALS9 (0.40) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA | |
| SCHEMBL15071561 | 1.00 | LGALS9 (0.40) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA | |
| SCHEMBL12452534 | 0.86 | ALDH1A1 (0.47) | LMNAKMT2AHTTALDH1A1TSHR | |
| SCHEMBL14929037 | 0.86 | LMNA (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA | |
| SCHEMBL18561531 | 0.86 | LMNA (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA | |
| SCHEMBL18671857 | 0.86 | LMNA (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA | |
| SCHEMBL38660515 | 0.76 | LGALS9 (0.48) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA | |
| SCHEMBL19866479 | 0.76 | LGALS9 (0.49) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA | |
| SCHEMBL12522983 | 0.75 | TRPM8 (0.42) | LMNAKMT2AMAPTHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201239-A1 | ALKYNYL NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E | Janssen Pharmaceuticals, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-01 | — | — | US | disclosed |
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2018-03-22 | — | — | US | disclosed |
| US-20180044369-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2018-02-15 | — | — | US | disclosed |
| US-9862743-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9815864-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170143749-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2017-05-25 | — | — | US | disclosed |
| US-20170143751-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2017-05-25 | — | — | US | disclosed |
| US-9603863-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9605018-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160016987-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20150366888-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-12-24 | — | — | US | disclosed |
| US-20150366887-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-12-24 | — | — | US | disclosed |
| US-20150141363-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150105341-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-04-16 | — | — | US | disclosed |
| US-8980865-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-01-08 | — | — | US | disclosed |
| US-20140179627-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20130164261-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201239-A1 | ALKYNYL NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E | HAVCR2, PNP, ENTPD5 | LGALS9 698/4885LGALS1 1164/4885LGALS3 1131/4885 |
| US-20140179910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | LGALS9 2942/4885LGALS1 3770/4885LGALS3 3839/4885 |
| US-20140179627-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | LGALS9 2942/4885LGALS1 3770/4885LGALS3 3839/4885 |
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | LGALS9 2942/4885LGALS1 3770/4885LGALS3 3839/4885 |
| US-20150366888-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, TYMP | LGALS9 2333/4885LGALS1 2852/4885LGALS3 3026/4885 |
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | LGALS9 2701/4885LGALS1 3492/4885LGALS3 3708/4885 |
| US-20180044369-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NUDT1 | LGALS9 3274/4885LGALS1 3748/4885LGALS3 3882/4885 |
| US-20170143749-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, TYMP | LGALS9 2333/4885LGALS1 2852/4885LGALS3 3026/4885 |
| US-20130164261-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | LGALS9 4580/4885LGALS1 4793/4885LGALS3 4799/4885 |
| US-20170143751-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | LGALS9 3153/4885LGALS1 3862/4885LGALS3 3935/4885 |
| US-20150105341-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NUDT1 | LGALS9 3274/4885LGALS1 3748/4885LGALS3 3882/4885 |
| US-20160016987-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | LGALS9 2942/4885LGALS1 3770/4885LGALS3 3839/4885 |
| US-20150141363-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | LGALS9 4580/4885LGALS1 4793/4885LGALS3 4799/4885 |
| US-20150366887-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | LGALS9 3153/4885LGALS1 3862/4885LGALS3 3935/4885 |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | LGALS9 2701/4885LGALS1 3492/4885LGALS3 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.